Integrative radiogenomics for virtual biopsy and treatment monitoring in ovarian cancer.
Ovarian cancer
Radiogenomics
Radiomics
Tumour habitats
Virtual biopsies
Journal
Insights into imaging
ISSN: 1869-4101
Titre abrégé: Insights Imaging
Pays: Germany
ID NLM: 101532453
Informations de publication
Date de publication:
17 Aug 2020
17 Aug 2020
Historique:
received:
27
04
2020
accepted:
16
07
2020
entrez:
18
8
2020
pubmed:
18
8
2020
medline:
18
8
2020
Statut:
epublish
Résumé
Ovarian cancer survival rates have not changed in the last 20 years. The majority of cases are High-grade serous ovarian carcinomas (HGSOCs), which are typically diagnosed at an advanced stage with multiple metastatic lesions. Taking biopsies of all sites of disease is infeasible, which challenges the implementation of stratification tools based on molecular profiling. In this review, we describe how these challenges might be overcome by integrating quantitative features extracted from medical imaging with the analysis of paired genomic profiles, a combined approach called radiogenomics, to generate virtual biopsies. Radiomic studies have been used to model different imaging phenotypes, and some radiomic signatures have been associated with paired molecular profiles to monitor spatiotemporal changes in the heterogeneity of tumours. We describe different strategies to integrate radiogenomic information in a global and local manner, the latter by targeted sampling of tumour habitats, defined as regions with distinct radiomic phenotypes. Linking radiomics and biological correlates in a targeted manner could potentially improve the clinical management of ovarian cancer. Radiogenomic signatures could be used to monitor tumours during the course of therapy, offering additional information for clinical decision making. In summary, radiogenomics may pave the way to virtual biopsies and treatment monitoring tools for integrative tumour analysis.
Sections du résumé
BACKGROUND
BACKGROUND
Ovarian cancer survival rates have not changed in the last 20 years. The majority of cases are High-grade serous ovarian carcinomas (HGSOCs), which are typically diagnosed at an advanced stage with multiple metastatic lesions. Taking biopsies of all sites of disease is infeasible, which challenges the implementation of stratification tools based on molecular profiling.
MAIN BODY
METHODS
In this review, we describe how these challenges might be overcome by integrating quantitative features extracted from medical imaging with the analysis of paired genomic profiles, a combined approach called radiogenomics, to generate virtual biopsies. Radiomic studies have been used to model different imaging phenotypes, and some radiomic signatures have been associated with paired molecular profiles to monitor spatiotemporal changes in the heterogeneity of tumours. We describe different strategies to integrate radiogenomic information in a global and local manner, the latter by targeted sampling of tumour habitats, defined as regions with distinct radiomic phenotypes.
CONCLUSION
CONCLUSIONS
Linking radiomics and biological correlates in a targeted manner could potentially improve the clinical management of ovarian cancer. Radiogenomic signatures could be used to monitor tumours during the course of therapy, offering additional information for clinical decision making. In summary, radiogenomics may pave the way to virtual biopsies and treatment monitoring tools for integrative tumour analysis.
Identifiants
pubmed: 32804260
doi: 10.1186/s13244-020-00895-2
pii: 10.1186/s13244-020-00895-2
pmc: PMC7431480
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
94Subventions
Organisme : Cancer Research UK
ID : 15601
Pays : United Kingdom
Références
Radiology. 2011 Mar;258(3):906-14
pubmed: 21339352
Eur Radiol. 2018 Nov;28(11):4849-4859
pubmed: 29737390
Oncogene. 2005 Apr 18;24(17):2776-86
pubmed: 15838514
Clin Cancer Res. 2008 Apr 15;14(8):2357-62
pubmed: 18413825
Nat Rev Cancer. 2011 Sep 23;11(10):719-25
pubmed: 21941283
Nat Commun. 2014 Jun 03;5:4006
pubmed: 24892406
Int J Mol Sci. 2019 Feb 22;20(4):
pubmed: 30813239
Radiology. 2017 Nov;285(2):482-492
pubmed: 28641043
Sci Rep. 2015 Aug 17;5:13087
pubmed: 26278466
J Am Coll Radiol. 2015 Aug;12(8):862-6
pubmed: 26250979
Drug Resist Updat. 2016 Jan;24:55-69
pubmed: 26830315
Eur Radiol. 2018 Jan;28(1):356-362
pubmed: 28755054
Radiology. 2019 Dec;293(3):583-591
pubmed: 31573400
Cell. 2006 Dec 1;127(5):905-15
pubmed: 17129778
Nat Rev Cancer. 2017 Oct;17(10):605-619
pubmed: 28912577
Radiology. 2016 Feb;278(2):563-77
pubmed: 26579733
N Engl J Med. 2017 Jun 1;376(22):2109-2121
pubmed: 28445112
J Magn Reson Imaging. 2018 Mar;47(3):604-620
pubmed: 29095543
Clin Cancer Res. 2016 Aug 1;22(15):3801-9
pubmed: 26936916
Int J Radiat Oncol Biol Phys. 2018 Aug 1;101(5):1179-1187
pubmed: 29908785
J Med Imaging (Bellingham). 2018 Jan;5(1):011004
pubmed: 29098169
Eur J Obstet Gynecol Reprod Biol. 2017 Jun;213:123-139
pubmed: 28457647
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
Radiology. 2014 Aug;272(2):374-84
pubmed: 24702725
Radiology. 2016 Jul;280(1):261-70
pubmed: 27082783
Eur Radiol. 2017 Sep;27(9):3583-3592
pubmed: 28168370
N Engl J Med. 2012 Mar 8;366(10):883-892
pubmed: 22397650
Oncotarget. 2016 Aug 16;7(33):53362-53376
pubmed: 27438142
Nat Rev Cancer. 2015 Nov;15(11):668-79
pubmed: 26493647
J Urol. 2011 Nov;186(5):1818-24
pubmed: 21944089
Expert Rev Precis Med Drug Dev. 2016;1(2):207-226
pubmed: 28042608
Radiology. 2017 Nov;285(2):472-481
pubmed: 28628421
Cancer Genet. 2012 Jan-Feb;205(1-2):34-41
pubmed: 22429596
Insights Imaging. 2020 Feb 10;11(1):22
pubmed: 32040647
Nat Genet. 2013 Oct;45(10):1127-33
pubmed: 24071851
J Clin Pathol. 2017 Nov;70(11):984-987
pubmed: 28596154
Elife. 2017 Jul 21;6:
pubmed: 28731408
Clin Cancer Res. 2009 Feb 15;15(4):1417-27
pubmed: 19193619
Front Oncol. 2014 Apr 17;4:81
pubmed: 24860781
JAMA. 2011 Oct 12;306(14):1557-65
pubmed: 21990299
Br J Radiol. 2017 Feb;90(1070):20160665
pubmed: 27936886
Nat Rev Immunol. 2015 Feb;15(2):73-86
pubmed: 25614318
Radiology. 2015 Mar;274(3):742-51
pubmed: 25383459
Nat Commun. 2019 Feb 15;10(1):764
pubmed: 30770825
Eur J Cancer. 2012 Mar;48(4):441-6
pubmed: 22257792
Arch Gynecol Obstet. 2017 Mar;295(3):569-576
pubmed: 28154920
Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):1143-1158
pubmed: 30170872
Eur Radiol. 2020 Aug;30(8):4306-4316
pubmed: 32253542
Mol Cell Biol. 2016 Jan 11;36(7):1050-63
pubmed: 26755558
J Clin Invest. 2013 Sep;123(9):3740-50
pubmed: 23945238
Phys Med. 2017 Jun;38:122-139
pubmed: 28595812
Insights Imaging. 2020 Jan 3;11(1):1
pubmed: 31901171
Cancers (Basel). 2018 Dec 26;11(1):
pubmed: 30587822
Crit Rev Oncol Hematol. 2014 Feb;89(2):207-16
pubmed: 24071502
Nat Genet. 2013 Oct;45(10):1113-20
pubmed: 24071849
Cancer. 2012 Aug 1;118(15):3703-9
pubmed: 22139894
Eur Radiol Exp. 2018 Nov 14;2(1):36
pubmed: 30426318
J Magn Reson Imaging. 2017 Oct;46(4):1017-1027
pubmed: 28177554
Urology. 2018 Feb;112:209-214
pubmed: 29056576
Nat Biotechnol. 2007 Jun;25(6):675-80
pubmed: 17515910
Tomography. 2019 Mar;5(1):127-134
pubmed: 30854450
Nat Genet. 2016 Jul;48(7):758-67
pubmed: 27182968
Clin Radiol. 2017 Jan;72(1):3-10
pubmed: 27742105
NPJ Precis Oncol. 2018 Sep 17;2:20
pubmed: 30246154
Med Phys. 2018 Jun 13;:
pubmed: 29896896
Biomark Cancer. 2019 Jul 05;11:1179299X19860815
pubmed: 31308780
Clin Cancer Res. 2015 Jan 15;21(2):249-57
pubmed: 25421725
Nat Commun. 2017 Oct 23;8(1):1093
pubmed: 29061967
Eur Radiol. 2017 Sep;27(9):3991-4001
pubmed: 28289945
J Natl Cancer Inst. 2018 Jul 1;110(7):704-713
pubmed: 29788099
Clin Cancer Res. 2008 Aug 15;14(16):5198-208
pubmed: 18698038
Cancer Imaging. 2020 May 1;20(1):33
pubmed: 32357923
Cancer Res. 2017 Jul 15;77(14):3922-3930
pubmed: 28566328
Am Soc Clin Oncol Educ Book. 2017;37:443-448
pubmed: 28561656
Radiology. 2013 Oct;269(1):8-15
pubmed: 24062559
J Clin Invest. 2013 Jan;123(1):517-25
pubmed: 23257362
Radiother Oncol. 2018 Jun;127(3):349-360
pubmed: 29779918
Nat Rev Clin Oncol. 2017 Dec;14(12):749-762
pubmed: 28975929